What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

December 8, 2025Blood

Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

This phase 2 trial assesses the CR rate of epcoritamab and R-miniCVP in older DLBCL patients, indicating potential as a non-anthracycline option.

The trial aims to determine the CR rate after combined therapy in older patients with DLBCL who are unfit for anthracycline treatment.
The primary endpoint is the CR rate after 6 cycles, with 40-45% PFS currently seen in standard treatments.
In this study, older unfit patients receiving chemoimmunotherapy will get R-miniCVP plus epcoritamab from the second cycle.
These findings may highlight a promising new treatment pathway for patients who cannot tolerate anthracycline chemotherapy.

Shah et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This phase 2 trial assesses the CR rate of epcoritamab and R-miniCVP in older DLBCL patients, indicating potential as a non-anthracycline option.